Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
severe combined immunodeficiency
MeSH D016511 - severe combined immunodeficiency
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D000081207:
Primary immunodeficiency diseases
1 Company
1 Drug
$
Success rate
D007232:
Newborn infant diseases
0 Companies
0 Drugs
Success rate
D049914:
Dna repair-deficiency disorders
0 Companies
0 Drugs
Success rate
D016511:
Severe combined immunodeficiency
1 Company
1 Drug
$
Success rate
D053632:
X-linked combined immunodeficiency diseases
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Leadiant Biosciences
Pegademase bovine
Adagen
1990-03-21
Clinical Trials
Historical Success Rate
Phase 1
60
%
9/15
Phase 2
26
%
5/19
Phase 3
29
%
2/7
Approved:
1
Overall Success rate:
5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Leadiant Biosciences
Pegademase bovine
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use